Literature DB >> 30416569

A Risk Score to Predict the Absence of Left Ventricular Reverse Remodelling: Implications for the Timing of ICD Implantation in Primary Prevention.

Jordi Pérez-Rodon1, Enrique Galve1, Carmen Pérez-Bocanegra2, Teresa Soriano-Sánchez1, Jesús Recio-Iglesias2, Eva Domingo-Baldrich1, Mila Alzola-Guevara1, Ignacio Ferreira-Gonzalez3, Josep Ramon Marsal3, Aida Ribera-Solé3, Laura Gutierrez García-Moreno1, Luz María Cruz-Carlos4, Nuria Rivas-Gandara1, Ivo Roca-Luque1, Jaume Francisco-Pascual1, Artur Evangelista-Masip1, Àngel Moya-Mitjans1, David Garcia-Dorado1.   

Abstract

Entities:  

Keywords:  Heart failure; implantable cardioverter defibrillator; left ventricular reverse remodelling; pharmacological treatment optimization; risk score

Year:  2017        PMID： 30416569      PMCID： PMC6213222          DOI： 10.15420/ecr.2017:23:8

Source DB:  PubMed          Journal:  Eur Cardiol        ISSN： 1758-3756


× No keyword cloud information.
  2 in total

1.  Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score.

Authors:  Josep Lupón; Hanna K Gaggin; Marta de Antonio; Mar Domingo; Amparo Galán; Elisabet Zamora; Joan Vila; Judith Peñafiel; Agustín Urrutia; Elena Ferrer; Nuria Vallejo; James L Januzzi; Antoni Bayes-Genis
Journal:  Int J Cardiol       Date:  2015-02-17       Impact factor: 4.164

2.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

Authors:  M R Bristow; E M Gilbert; W T Abraham; K F Adams; M B Fowler; R E Hershberger; S H Kubo; K A Narahara; H Ingersoll; S Krueger; S Young; N Shusterman
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.